CDC researchers recently found that nearly half of tuberculosis (TB) patients in eight countries are resistant to at least one second-line drug, a "worrying" finding that they say may signal the emergence of "virtually untreatable" TB.
In a study published last week in The Lancet, CDC researchers examined 1,278 TB cases in Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea, and Thailand. They found that:
- 43.7% of TB cases were resistant to at least one second-line drug; and
- 6.7% of TB cases were "extensively drug-resistant," meaning resistant to first-line drugs and at least two second-line treatments in different classes.
"The global emergence of extensively drug-resistant tuberculosis heralds the advent of widespread, virtually untreatable tuberculosis," the study says.
The researchers found a correlation between the prevalence of drug resistance and the availability of second-line treatments. For example:
- In Thailand, where second-line drugs were introduced in the last decade, 33% of TB cases showed second-line drug resistance; and
- In South Korea and Russia, where second-line drugs have been available for more than 20 years, over 60% of TB patients showed second-line drug resistance.
"As more individuals are diagnosed with, and treated for, drug-resistant TB, more resistance to second-line drugs is expected to emerge," says Tracy Dalton, lead author of the study (Kelland, Reuters, 8/30; Kitamura/Narayan, Bloomberg, 8/30; Gever, MedPage Today, 8/30).
Next in the Daily Briefing
Federal judge dismisses ACA contraception lawsuit